Emergent BioSolutions stock faces lower 2026 revenue outlook

Emergent BioSolutions reported weaker third-quarter revenue and reduced its 2026 outlook on November 2, 2026. The results for the quarter ended September 30 were shaped by the timing of medical-countermeasure deliveries, according to BioSpace.

Revenue timing clouds full-year outlook

Revenue fell 52 percent year over year to 110.0 million US dollars, while the company posted a net loss of 32.7 million US dollars. Adjusted EBITDA was negative 4.6 million US dollars, and adjusted gross margin fell to 28 percent from 62 percent a year earlier.

Management cut full-year revenue guidance to 600 million to 645 million US dollars from 645 million to 675 million. Adjusted EBITDA guidance was reduced to 110 million to 140 million US dollars from 130 million to 150 million, while adjusted gross-margin guidance rose to 45 percent to 47 percent.

Naloxone revenue declined 42 percent to 43.5 million US dollars, reflecting lower over-the-counter NARCAN sales and an unfavorable price-volume mix in US public-interest channels. Medical-countermeasure revenue also weakened as smallpox and other product deliveries shifted, although anthrax revenue benefited from higher CYFENDUS deliveries.

Emergent BioSolutions stock traded at 5.25 euros on Lang & Schwarz at 11:00 p.m. CET on Wednesday, November 4, 2026. Investors can follow the real-time quote of Emergent BioSolutions stock.

Business model and competitive position

Emergent BioSolutions develops protective and life-saving products for public-health threats including smallpox, mpox, botulism, Ebola, anthrax and opioid overdoses, with operations centered on commercial products, medical countermeasures and services. Its portfolio includes NARCAN and KLOXXADO as well as vaccines and treatments supplied to government customers, and the company is based in the United States, according to its investor relations profile. In the broader competitive landscape, Distill lists Catalent, Lonza and Bavarian Nordic among comparable companies, reflecting Emergent's mix of biopharmaceutical manufacturing, vaccines and biodefense products. Emergent is more specialized in public-health preparedness and government-linked medical countermeasures than the broader contract-manufacturing businesses of Catalent and Lonza.

The broader US market is tracked through the S&P 500 market page.

More news and analyses on Emergent BioSolutions stock